Targeted Genetics Announces Appointment of Michael S. Perry, 18 Year Biotechnology/Pharmaceutical Industry Veteran, to Its Board of Directors.SEATTLE -- Targeted Genetics Corporation (Nasdaq: TGEN TGEN Traffic Generator TGEN Table Generate TGEN Test Generator ) announced today that it has appointed Michael S. Perry, D.V.M., Ph.D., to its board of directors. Dr. Perry brings over 18 years of successful biotechnology and pharmaceutical management experience. He has a proven track record in research and development innovation with special emphasis on product development and approval, strategic portfolio management, integration of company mergers and acquisitions, business development, and driving shareholder value. Dr. Perry is currently Chief Development Officer at VIA Pharmaceuticals, Inc., a company that is developing therapeutics to treat cardiovascular inflammation at the level of the vessel wall to stabilize the disease process and reduce cardiovascular events. "Mike adds extensive technical expertise in traditional and cutting-edge biomedical science to our Board of Directors," said H. Stewart Parker, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Targeted Genetics. "In addition, his widespread knowledge in strategic business development transactions and product assessment will be important as we continue to execute on our partnership and broader business strategies. I believe Mike's experience will be particularly relevant and valuable to achieving our ongoing goals and objectives." Previous to his role at VIA Pharmaceuticals, Dr. Perry was President, Chief Executive Officer and Co-founder of Extropy Noun 1. extropy - the prediction that human intelligence and technology will enable life to expand in an orderly way throughout the entire universe forecasting, foretelling, prediction, prognostication - a statement made about the future Pharmaceuticals, Inc., a pediatric-focused specialty pharmaceutical company. Dr. Perry also served as President, CEO and Director of Pharsight Corporation; Worldwide Head of Global R&D of Baxter's BioPharmaceuticals Business, a division of Baxter Healthcare Corporation; President, CEO and Director of SyStemix Inc. and Genetic Therapy Inc., two wholly owned Biotech subsidiaries of Sandoz/Novartis Pharma, as well as held various management positions in regulatory and scientific affairs at Novartis, Syntex Corporation, Schering-Plough Corporation and BioResearch bi·o·re·search n. Research in the biological sciences. Laboratories, Inc. Dr. Perry has also held previous board positions with BioTransplant, California Healthcare Institute, Arriva Pharmaceuticals, Pharsight Corporation, and Extropy Pharmaceuticals. Dr. Perry holds a B.Sc. in Physics, a Ph.D. in Biomedical Science with a specialization in Cardiopulmonary Pharmacology and a doctorate in Veterinary Medicine veterinary medicine, diagnosis and treatment of diseases of animals. An early interest in animal diseases is found in ancient Greek writings on medicine. Veterinary medicine began to achieve the stature of a science with the organization of the first school in the & Surgery (D.V.M.) from the University of Guelph The University of Guelph is a medium-sized university located in Guelph, Ontario, established in 1964. While the U of G offers degrees in many different disciplines, the university is best known for its focus on life sciences, based in part on a long-standing history of , Ontario, Canada. "I look forward to serving on the Targeted Genetics Board of Directors," said Perry. "The company has a proven AAV AAV Adeno-Associated Virus AAV Asian-American Village AAV Amphibious Assault Vehicle (US DoD) AAV Association of Avian Veterinarians AAV All Activity Vehicle (Mercedes-Benz) AAV Airborne Assault Vehicle technology platform that shows promise in the genetic therapeutics marketplace and is an attractive attribute to potential partners. I look forward to contributing to Targeted Genetics' continuing future success as an independent director." Dr. Michael Perry has been appointed as a director to fill the vacant board seat resulting from Dr. Mark Richmond's recent retirement. About Targeted Genetics Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis and other acquired and inherited diseases with significant unmet medical need. We use our considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Our product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. , Huntington's disease Huntington's disease, hereditary, acute disturbance of the central nervous system usually beginning in middle age and characterized by involuntary muscular movements and progressive intellectual deterioration; formerly called Huntington's chorea. and hyperlipidemia hyperlipidemia /hy·per·lip·id·emia/ (-lip?i-de´me-ah) elevated concentrations of any or all of the lipids in the plasma, including hypertriglyceridemia, hypercholesterolemia, etc. . To learn more about Targeted Genetics, visit our website at www.targetedgenetics.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release contains forward-looking statements regarding our business strategy, our product development and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q Form 10-Q See 10-Q. for the period ended June 30, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion